Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and Insertion of the selection cassette in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CCN1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The CYR61/CCN1 protein also known simply as CYR61 CCN1 or CYR61 protein is a cellular protein with a molecular weight of approximately 40 kDa. It is a member of the CCN family of regulatory proteins which includes connective tissue growth factors. CYR61 is secreted into the extracellular matrix and has a critical role in cell adhesion and signaling. The protein is expressed in various tissues with higher levels observed in the placenta lungs and kidneys reflecting its role in organ development and repair processes.
Biological function summary
The CYR61/CCN1 protein acts as a signaling molecule that influences cell proliferation migration and adhesion. It interacts with integrins and heparan sulfate proteoglycans on the cell surface facilitating cellular communication that is essential for structural and functional tissue integrity. Additionally CYR61 is a part of multiprotein complexes impacting angiogenesis and inflammation. These activities place CYR61/CCN1 at a pivotal point in wound healing and vascularization processes.
Pathways
The CYR61/CCN1 protein participates in key signaling pathways such as the MAPK/ERK and Wnt pathways. These pathways modulate gene expression related to cell growth and differentiation. CYR61 collaborates with other proteins including VEGF and FGF to regulate cardiovascular development and morphogenesis. The interaction with these pathways highlights the protein’s integral role in cellular homeostasis and response to physiological changes.
CYR61/CCN1 is linked to cancer progression and fibrotic diseases. Elevated levels of this protein are frequently found in breast cancer emphasizing its role in tumor growth and metastasis. It associates with other proteins like TGF-beta during fibrotic responses contributing to the pathology of fibrosis in organs such as the liver and lungs. The involvement in these processes highlights its potential as a therapeutic target in oncology and fibrotic disease management.
